ES2664584B2 - Nanoparticulas con interiores protegidos, y métodos de uso de las mismas - Google Patents

Nanoparticulas con interiores protegidos, y métodos de uso de las mismas Download PDF

Info

Publication number
ES2664584B2
ES2664584B2 ES201631221A ES201631221A ES2664584B2 ES 2664584 B2 ES2664584 B2 ES 2664584B2 ES 201631221 A ES201631221 A ES 201631221A ES 201631221 A ES201631221 A ES 201631221A ES 2664584 B2 ES2664584 B2 ES 2664584B2
Authority
ES
Spain
Prior art keywords
nanoparticles
methods
therapeutic molecules
species
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201631221A
Other languages
English (en)
Other versions
ES2664584A1 (es
Inventor
María Josefa ALONSO FERNÁNDEZ
Zhigao Niu
Manuel Jesús SANTANDER ORTEGA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidade de Santiago de Compostela
Original Assignee
Universidade de Santiago de Compostela
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade de Santiago de Compostela filed Critical Universidade de Santiago de Compostela
Priority to ES201631221A priority Critical patent/ES2664584B2/es
Priority to US15/350,653 priority patent/US10471020B2/en
Priority to PCT/ES2017/070617 priority patent/WO2018050942A1/es
Publication of ES2664584A1 publication Critical patent/ES2664584A1/es
Application granted granted Critical
Publication of ES2664584B2 publication Critical patent/ES2664584B2/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Nanopartículas con interiores protegidos, y métodos de uso de las mismas. La presente invención se refiere en general a partículas, incluyendo nanopartículas, por ejemplo, para la administración de fármacos u otras aplicaciones. Ciertos aspectos de la presente invención se dirigen generalmente a partículas, tales como nanopartículas, que comprende una parte interior y un recubrimiento. La parte interior puede contener insulina u otras moléculas terapéuticas para la administración a un ser vivo. En algunos casos, las moléculas pueden estar electrostáticamente complejadas con un péptido de carga opuesta, tal como un oligoarginina, u otras especies. Las especies típicamente están cargadas positivamente, por ejemplo, para moléculas terapéuticas ionizadas negativamente a pH neutro. Las moléculas terapéuticas pueden ser también solubles en agua. En algunos casos, el péptido puede conjugarse con una porción hidrófoba, tales como colesterol, ácido láurico, o una cadena de ácido graso.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
ES201631221A 2016-09-19 2016-09-19 Nanoparticulas con interiores protegidos, y métodos de uso de las mismas Active ES2664584B2 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ES201631221A ES2664584B2 (es) 2016-09-19 2016-09-19 Nanoparticulas con interiores protegidos, y métodos de uso de las mismas
US15/350,653 US10471020B2 (en) 2016-09-19 2016-11-14 Nanoparticles with protected interiors, and methods of use thereof
PCT/ES2017/070617 WO2018050942A1 (es) 2016-09-19 2017-09-18 Nanopartículas con interiores protegidos, y métodos de uso de las mismas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201631221A ES2664584B2 (es) 2016-09-19 2016-09-19 Nanoparticulas con interiores protegidos, y métodos de uso de las mismas

Publications (2)

Publication Number Publication Date
ES2664584A1 ES2664584A1 (es) 2018-04-20
ES2664584B2 true ES2664584B2 (es) 2018-12-13

Family

ID=61617373

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201631221A Active ES2664584B2 (es) 2016-09-19 2016-09-19 Nanoparticulas con interiores protegidos, y métodos de uso de las mismas

Country Status (3)

Country Link
US (1) US10471020B2 (es)
ES (1) ES2664584B2 (es)
WO (1) WO2018050942A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2664584B2 (es) 2016-09-19 2018-12-13 Universidade De Santiago De Compostela Nanoparticulas con interiores protegidos, y métodos de uso de las mismas
CN109260174B (zh) * 2018-09-04 2021-10-15 中山大学 一种治疗性蛋白纳米颗粒的高通量制备方法
WO2021011398A1 (en) * 2019-07-12 2021-01-21 The Board Of Trustees Of The Leland Stanford Junior University Functionalized nanoparticles and their use in treating bacterial infections
CN113075342B (zh) * 2020-01-04 2024-02-27 东莞市东阳光仿制药研发有限公司 一种分离检测德谷胰岛素侧链有关物质的方法
US12458665B2 (en) 2020-03-26 2025-11-04 Cenyx Biotech Inc. Cerium oxide nanocomposite and use thereof
CN114617974B (zh) * 2020-12-10 2023-10-03 中国科学院苏州纳米技术与纳米仿生研究所 一种多肽白蛋白纳米粒及其制备方法和应用
US11998615B2 (en) 2021-04-14 2024-06-04 The Board Of Trustees Of The Leland Stanford Junior University Functionalized nanoparticles and their use in treating bacterial infections
US12161665B2 (en) 2021-09-23 2024-12-10 Cenyx Biotech Inc. Cerium oxide nanocomplex and a composition for preventing or treating liver failure comprising the same
US12303568B2 (en) * 2021-09-23 2025-05-20 Cenyx Biotech Inc. Cerium oxide nanocomplex and a composition for preventing or treating peritonitis comprising the same
EP4652991A1 (en) * 2024-05-22 2025-11-26 Universidade de Santiago de Compostela Nanoassemblies for the intracellular delivery of active principles of aminoacidic nature

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4628955B2 (ja) 2003-10-01 2011-02-09 独立行政法人科学技術振興機構 核移行能を有するポリアルギニン修飾リポソーム
US8709472B1 (en) 2007-11-13 2014-04-29 Abbott Cardiovascular Systems Inc. Bioactive agent-loaded heart-targeting nanoparticles
US9566349B2 (en) 2010-10-14 2017-02-14 Rutgers, The State University Of New Jersey Intestinal peptide targeting ligands
ES2385995B2 (es) 2011-01-10 2013-05-21 Universidade De Santiago De Compostela Nanocápsulas con cubierta polimérica
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
CN104434806B (zh) 2014-11-06 2017-05-03 中国人民解放军第四军医大学 一种具有高载药量及主动靶向效应的脂质混合plga纳米粒
CN104497147B (zh) 2014-12-23 2018-07-03 四川大学 一种双受体识别的串联型穿膜肽修饰的肿瘤靶向纳米递药系统
ES2664584B2 (es) 2016-09-19 2018-12-13 Universidade De Santiago De Compostela Nanoparticulas con interiores protegidos, y métodos de uso de las mismas

Also Published As

Publication number Publication date
ES2664584A1 (es) 2018-04-20
US10471020B2 (en) 2019-11-12
US20180078510A1 (en) 2018-03-22
WO2018050942A1 (es) 2018-03-22
WO2018050942A8 (es) 2018-05-11

Similar Documents

Publication Publication Date Title
ES2664584B2 (es) Nanoparticulas con interiores protegidos, y métodos de uso de las mismas
CL2019001366A1 (es) Formulaciones tamponadas exendina (9-39).
BR112014013151A2 (pt) dispositivo de microagulhas incluindo um agente terapêutico peptídeo e um aminoácido, métodos para produzir e usar o dispositivo
EP4286012A3 (en) Compounds and compositions for intracellular delivery of therapeutic agents
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
MX384232B (es) Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones.
WO2016042163A3 (en) Ophthalmic drug compositions
AR091308A1 (es) Nanoparticulas que comprenden una proteina hidrofoba vegetal y un disolvente organico no volatil miscible en agua y usos de las mismas, procedimiento, composicion
MX2012014079A (es) Lipidos biodegradables para la administracion de agentes activos.
WO2016040887A3 (en) Multilamellar lipid vesicle compositions and methods of use
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
IN2014MN02213A (es)
MX2015015409A (es) Proceso para la preparacion de eritrocitos cargados con una o mas sustancias de interes farmaceutico y eritrocitos asi obtenidos.
GT201700184A (es) Nuevas proteínas específicas para pioverdina y pioquelina
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
AR114325A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
CL2017000120A1 (es) Composiciones en suspensión de ciclosporina a para inyecciones subconjuntivales y perioculares
AR105237A1 (es) Método y composiciones nutricionales que contienen fosfatidiletanolamina, esfingomielina y ácido docosahexaenoico
EA201791147A1 (ru) Фармацевтическая композиция, ее получение и применения
MX2015017202A (es) Formulacion de liberacion modificada.
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
EA201791138A1 (ru) Фармацевтическая композиция, ее приготовление и применения
WO2017156078A3 (en) Delivery of nitric oxide-releasing phospholipids, liposomes, and high density lipoprotein-like nanoparticles (hdl nps) by drug eluting stents and intra-arterial injection
AU2018286475A8 (en) Non-viral gene delivery agent comprising lipopeptide (LP) compounds
WO2014204854A8 (en) Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2664584

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20181213